Uncategorized
Argenx jumps on Phase 3 data for blockbuster Vyvgart
The latest results give investors confidence in the drug’s ability to be approved in another indication for which there are no approved treatments.
The latest results give investors confidence in the drug’s ability to be approved in another indication for which there are no approved treatments.